Nanoparticle immune activators for glioblastoma
Spherical Nucleic Acid nano-architectures as first-in-class cGAS agonists for the immunotherapeutic treatment of Glioblastoma.
This project is developing tiny nanoparticle medicines that turn on the immune system to attack glioblastoma brain tumors in people with advanced or recurrent disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11143819 on NIH RePORTER |
What this research studies
I learned they are designing spherical nanoparticles that carry DNA-like molecules to activate the cGAS/STING immune pathway inside tumors. The plan is to deliver these particles directly into brain tumors so natural killer cells and T cells can better recognize and kill cancer cells. The team has tested related nanoparticles in lab and animal models and is working to improve stability and delivery to the tumor site. If those steps go well, the approach could move toward use during surgery or by direct injection in patients.
Who could benefit from this research
Good fit: People with glioblastoma, especially those whose tumors can be reached for direct injection or treated at the time of surgery, would be the best candidates.
Not a fit: Patients whose tumors are inaccessible to direct injection or who have other types of brain tumors may not benefit from this approach.
Why it matters
Potential benefit: If successful, this approach could boost anti-tumor immune responses in glioblastoma and may help shrink tumors or extend survival.
How similar studies have performed: Related STING-activating compounds and earlier spherical nucleic acid therapies have shown anti-tumor effects in animal glioblastoma models and some early human trials, but delivery and stability remain known challenges.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Stegh, Alexander H. — Washington University
- Study coordinator: Stegh, Alexander H.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.